Behind the Ozempic Shortage: The Science & Controversy Around Compounded GLP-1’s

About this video

Dr. Lyon interviews Shawn Norian, CEO of Empower Pharmacy, about the controversy surrounding compounded GLP-1 medications. Norian argues that large pharmaceutical companies are using regulatory pressure and legal action to eliminate compounding pharmacy competition in order to maintain monopoly pricing on weight loss drugs. He contends that compounded GLP-1s are legal, safe, and provide affordable access to medications that seven out of eight patients cannot otherwise afford at branded prices exceeding $500 monthly.

Key takeaways

• Norian claims compounding pharmacies are heavily regulated by the FDA and state boards, meeting the same manufacturing standards as large pharmaceutical companies, and that compounded GLP-1s remain legal as long as they differ from commercial products in strength, form, or combination
• The speaker alleges that pharmaceutical companies charge Americans up to 10 times more than Europeans for the same drugs and that compounding pharmacies have captured an estimated 50% of the GLP-1 market by offering significantly lower prices
• Norian argues that recent FDA warning letters and Eli Lilly’s lawsuit against his company represent coordinated efforts by big pharma to eliminate competition through regulatory capture and legislative influence funded by hundreds of millions in annual lobbying

Episode details: published April 22, 2025 · 23.5K views · 1:14:51 long. Summary written by Self Growth Videos from the episode itself. The health and muscle concepts described are Dr. Gabrielle Lyon’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices.

← Previous: The Science of Optimal Hormone Health | Dr. Melanie Cree PHD · Next: Future of GLP1s like Ozempic →

All Dr. Gabrielle Lyon videos · Dr. Gabrielle Lyon profile · Dr. Gabrielle Lyon on YouTube